Ge Wang

Mr. Ge Wang

Shanghai Jiaotong University School of medicine, Shanghai, China
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HSHan Sun
Han Sun
YZYu Zhang
Yu Zhang
GWGe Wang
Ge Wang
WYWen Yang
Wen Yang
YXYingjie Xu
Yingjie Xu
Over the past two decades, significant technological innovations have led to messenger RNA (mRNA) becoming a promising option for developing prophylactic and therapeutic vaccines, protein replacement therapies, and genome engineering. The success of the two COVID-19 mRNA vaccines has sparked new enthusiasm for other medical applications, particularly in cancer treatment. In vitro-transcribed (IVT) mRNAs are structurally designed to resemble naturally occurring mature mRNA. Delivery of IVT mRNA via delivery platforms such as lipid nanoparticles allows host cells to produce many copies of encoded proteins, which can serve as antigens to stimulate immune responses or as additional beneficial proteins for supplements. mRNA-based cancer therapeutics include mRNA cancer vaccines, mRNA encoding cytokines, chimeric antigen receptors, tumor suppressors, and other combination therapies. To better understand the current development and research status of mRNA therapies for cancer treatment, this review focused on the molecular design, delivery systems, and clinical indications of mRNA therapies in cancer.

5 September 2022 in Molecules
Verified
Journal Article
Open access
PDF file
GWGe Wang
Ge Wang
YByuhao Bai
yuhao Bai
JCJiarui Cui
Jiarui Cui
ZZZirui Zong
Zirui Zong
YGYuan Gao
Yuan Gao
ZZzhen zheng
zhen zheng
The Rat Sarcoma (RAS) family (NRAS, HRAS, and KRAS) is endowed with GTPase activity to regulate various signaling pathways in ubiquitous animal cells. As proto-oncogenes, RAS mutations can maintain activation, leading to the growth and proliferation of abnormal cells and the development of a variety of human cancers. For the fight against tumors, the discovery of RAS-targeted drugs is of high significance. On the one hand, the structural properties of the RAS protein make it difficult to find inhibitors specifically targeted to it. On the other hand, targeting other molecules in the RAS signaling pathway often leads to severe tissue toxicities due to the lack of disease specificity. However, computer-aided drug design (CADD) can help solve the above problems. As an interdisciplinary approach that combines computational biology with medicinal chemistry, CADD has brought a variety of advances and numerous benefits to drug design, such as the rapid identification of new targets and discovery of new drugs. Based on an overview of RAS features and the history of inhibitor discovery, this review provides insight into the application of mainstream CADD methods to RAS drug design.

11 April 2026 in Nature Communications
Verified
Journal Article
Open access
DHDexuan He
Dexuan He
XZXiao Zhou
Xiao Zhou
WGWenbin Guan
Wenbin Guan
LZLiyuan Zhang
Liyuan Zhang
XZXiaoman Zhang
Xiaoman Zhang
WXWeidi Xie
Weidi Xie
Rare cancers comprise 20-25% of malignancies (over 70% in pediatric oncology) but face major diagnostic challenges due to limited expert availability. While pathology vision-language models show promising zero-shot capabilities for common cancers, their performance on rare cancers remains limited. Existing multi-instance learning (MIL) methods rely solely on visual features, overlooking cross-modal knowledge and compromising interpretability critical for rare cancer diagnosis. To address this, we propose PathPT, a framework that exploits vision-language foundation models through spatially-aware visual aggregation and task-specific prompt tuning. PathPT converts WSI-level supervision into fine-grained tile-level guidance, preserving tumor localization and enabling cross-modal reasoning. Across eight rare and three common cancer datasets-spanning 56 subtypes and 3958 WSIs, PathPT consistently outperforms state-of-the-art methods under data-scarce settings. It achieves substantial gains in both subtyping accuracy and cancerous region grounding ability, providing a scalable, interpretable AI solution to improve rare cancer subtyping with limited access to specialized expertise.

1 May 2022 in Chinese Science Bulletin
Verified
Journal Article
Closed access
GWGe Wang
Ge Wang
YBYuhao Bai
Yuhao Bai
ZWZexuan Wang
Zexuan Wang
YXYingjie Xu
Yingjie Xu